6533b85bfe1ef96bd12baba5
RESEARCH PRODUCT
Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors
Erkka SyvälahtiEsa R. KorpiJarmo HietalaHartmut LüddensMikko KuoppamäkiGarry Wongsubject
Malemedicine.medical_specialtyTime Factorsmedicine.drug_classDrug Evaluation PreclinicalDesmethylclozapineIn Vitro TechniquesPharmacologyBiologyGABA AntagonistsRats Sprague-Dawleychemistry.chemical_compoundInternal medicinemedicineHaloperidolAnimalsGABA-A Receptor AntagonistsReceptorClozapineClozapinePharmacologyBenzodiazepineGABAA receptorBrainRatsLogistic ModelsEndocrinologychemistryConvulsantHaloperidolFlunitrazepamAntipsychotic Agentsmedicine.drugdescription
Abstract Similarly to clozapine, a clozapine metabolite, N -desmethylclozapine, but not clozapine N -oxide, antagonized brain γ-aminobutyric acid type A (GABA A ) receptors at high micromolar concentrations. However, daily subcutaneous injections of clozapine (10 and 25 mg/kg) and haloperidol (0.5 mg/kg) for 14 days failed to alter the modulation by GABA of rat cerebrocortical and cerebellar benzodiazepine ([ 3 H]flunitrazepam) or convulsant ( t -[ 35 S]bicyclophosphorothionate) binding sites of the GABA A receptor. The results thus suggest that the GABA A receptor antagonism exerted by chronic in vivo clozapine treatment is weak as compared to this treatment's actions on certain monoamine receptors and is unlikely to be involved in the therapeutic actions of clozapine.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1996-10-31 | European Journal of Pharmacology |